Get the Stockscreener App
312.10
1.06%
-3.18
Overview
News
Price History
Option Chain
Financials
Why CI Down?
Discussions
Forecast
Stock Split
Dividend History
Cigna Group stock is traded at $312.10, with a volume of 734.59K.
It is down -1.06% in the last 24 hours and down -6.83% over the past month.
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is with the Department of Defense (current contract through 2029), and it recently won a multiyear deal with top-tier insurer Centene. In health insurance and other benefits, Cigna primarily serves employers through self-funding arrangements, and the company operates mostly in the US with 17 million US and 2 million international medical members covered as of December 2024.
See More
Previous Close:
$315.28
Open:
$314.98
24h Volume:
734.59K
Relative Volume:
0.42
Market Cap:
$83.32B
Revenue:
$254.47B
Net Income/Loss:
$5.03B
P/E Ratio:
17.28
EPS:
18.06
Net Cash Flow:
$6.01B
1W Performance:
-1.62%
1M Performance:
-6.83%
6M Performance:
-7.30%
1Y Performance:
-6.38%
1-Day Range:
$310.29
$315.80
1-Week Range:
$310.20
$316.99
52-Week Range:
$262.03
$370.82
Cigna Group Stock (CI) Company Profile
Name
Cigna Group
Sector
Industry
Phone
(860) 226-6000
Address
900 COTTAGE GROVE ROAD, BLOOMFIELD, CT
Compare CI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CI
Cigna Group
|
311.91 | 86.82B | 254.47B | 5.03B | 6.01B | 18.06 |
|
UNH
Unitedhealth Group Inc
|
298.71 | 291.72B | 410.06B | 22.11B | 24.86B | 23.88 |
|
ELV
Elevance Health Inc
|
379.58 | 93.20B | 183.12B | 5.92B | 3.67B | 25.63 |
|
CVS
Cvs Health Corp
|
62.62 | 80.63B | 378.96B | 5.28B | 5.94B | 4.19 |
|
CNC
Centene Corp
|
56.31 | 30.83B | 163.07B | 3.31B | -490.00M | 6.24 |
Cigna Group Stock (CI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jun-26-24 | Initiated | Piper Sandler | Overweight |
| May-30-24 | Initiated | Robert W. Baird | Outperform |
| Mar-06-24 | Initiated | Barclays | Overweight |
| Feb-05-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-05-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-01-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-04-24 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-11-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-18-23 | Downgrade | Edward Jones | Buy → Hold |
| Jun-06-23 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-21-23 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-05-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-23-22 | Resumed | Morgan Stanley | Overweight |
| Nov-21-22 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jul-14-22 | Downgrade | Jefferies | Buy → Hold |
| Jun-22-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-17-22 | Initiated | Loop Capital | Hold |
| May-27-22 | Resumed | Bernstein | Mkt Perform |
| May-26-22 | Upgrade | BofA Securities | Underperform → Neutral |
| May-16-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-09-22 | Upgrade | Cowen | Market Perform → Outperform |
| Feb-07-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-04-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-06-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-21-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-16-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-14-21 | Initiated | Goldman | Neutral |
| Nov-17-21 | Initiated | Seaport Research Partners | Buy |
| Sep-27-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-10-21 | Downgrade | BofA Securities | Buy → Underperform |
| Sep-10-21 | Initiated | Cowen | Market Perform |
| Aug-06-21 | Reiterated | BofA Securities | Buy |
| Aug-06-21 | Reiterated | Citigroup | Buy |
| Aug-06-21 | Reiterated | Deutsche Bank | Buy |
| Aug-06-21 | Reiterated | Jefferies | Buy |
| Aug-06-21 | Reiterated | Mizuho | Buy |
| Aug-06-21 | Reiterated | Oppenheimer | Outperform |
| Aug-06-21 | Reiterated | Truist | Buy |
| May-19-21 | Initiated | Wells Fargo | Equal Weight |
| Jul-01-20 | Initiated | SVB Leerink | Mkt Perform |
| May-04-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Mar-24-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-11-19 | Downgrade | Wells Fargo | Market Perform → Underperform |
| Oct-18-19 | Initiated | Mizuho | Buy |
| Sep-30-19 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-12-19 | Initiated | Deutsche Bank | Buy |
| Aug-06-19 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Apr-23-19 | Initiated | UBS | Buy |
| Jan-14-19 | Initiated | Stephens | Overweight |
| Dec-24-18 | Initiated | Edward Jones | Buy |
| Mar-13-18 | Initiated | Bernstein | Mkt Perform |
| Mar-08-18 | Initiated | Barclays | Overweight |
| Jan-03-18 | Initiated | Goldman | Neutral |
| Nov-03-17 | Reiterated | RBC Capital Mkts | Outperform |
| Jun-22-17 | Reiterated | RBC Capital Mkts | Outperform |
| Jun-12-17 | Initiated | Credit Suisse | Outperform |
| Jun-07-17 | Initiated | Morgan Stanley | Overweight |
| May-08-17 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-05-17 | Initiated | Deutsche Bank | Buy |
View All
Cigna Group Stock (CI) Latest News
CVS or Cigna: Which Diversified Healthcare Stock Should You Own Now? - Zacks Investment Research
The Zacks Analyst Blog Highlights Costco Wholesale, Chubb, Cigna, Global Self Storage and Natural Health Trends - Yahoo Finance
Cigna’s SWOT analysis: stock poised for growth amid healthcare challenges - Investing.com
UBS Maintains Buy Rating on Cigna (CI) Stock - Insider Monkey
Molson Coors and Cigna Head My “Do Nothing” Stock List - TribLIVE.com
UBS maintains Cigna stock Buy rating with $390 target - Investing.com
Top Research Reports for Costco, Chubb & Cigna - Yahoo Finance
Guggenheim Reiterates Buy Rating for Cigna Group (CI) with $388 Price Target | CI Stock News - GuruFocus
Cigna Adds Kerecis Intact Fish-Skin Grafts to Coverage Policy - Business Wire
Cigna's (CI) Evernorth Secures Open Access for Key Products | CI Stock News - GuruFocus
Cigna Announced a New Agreement for Copay Caps on Eli Lilly and Novo Nordisk Weight Loss Drugs - MSN
FTC Scraps PepsiCo Price Discrimination Case In 3-0 Vote, Marking Major Shift As Trump-Era Leadership Reverses Biden CrackdownCVS Health (NYSE:CVS), Cigna Group (NYSE:CI) - Benzinga
Cigna is putting a cap on weight loss drug costs - Yahoo Finance
Cigna (CI) Caps Out-of-Pocket Costs on Weight-Loss Drugs for Pat - GuruFocus
Cigna (CI) Caps Out-of-Pocket Costs on Weight-Loss Drugs for Patients | CI Stock News - GuruFocus
Cigna (CI) Expands Access to Weight Loss Medications with New Ph - GuruFocus
Cigna (CI) Unit Launches Cost-Effective Pharmacy Benefit for Wei - GuruFocus
Cigna (CI) Launches Cost-Effective Benefit Option for Weight Loss Drugs | CI Stock News - GuruFocus
Cigna (CI) Caps Weight-Loss Drug Costs, Impact on Telehealth Offerings | CI Stock News - GuruFocus
Former employees sue Cigna's 401(k) fiduciaries for misusing forfeited employer match money - Pensions & Investments
Pharmalittle: We're reading about rising drug prices, Cigna's plan for weight loss drugs, and more - statnews.com
Cigna to offer $200 Wegovy, Zepbound weight-loss benefit - Reuters
Cigna (CI) Launches Cost-Capping Program for Weight-Loss Drugs - GuruFocus
Cigna’s Evernorth caps weight-loss drug copays at $200/month (CI:NYSE) - Seeking Alpha
Cigna Offers New Weight-Loss Drug Pricing Plan to Boost Use - Bloomberg.com
Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs - MSN
Cigna (CI) Faces Increased Scrutiny Amid Expanded Medicare Audits | CI Stock News - GuruFocus
Cigna Group's Evernorth Launches Benefit Option to Lower Weight Loss Medicine Costs - marketscreener.com
Cigna (CI) Affected by Medicare Advantage Audit Expansion | CI Stock News - GuruFocus
Evernorth Launches New Benefit Option That Drives Lower Net Cost for Weight Loss Medicines and Limits Patient Cost to No More Than $200 Per Month - Quantisnow
Cigna Accused of Misusing Retirement Plan Funds - USA Herald
Baird Adjusts Price Target on Cigna Group to $364 From $362, Maintains Outperform Rating - marketscreener.com
Cigna Accused Of Mismanaging Retirement Plan Funds - Law360
2nd Circ. Affirms Dismissal Of Lab's Payment Suit Against Cigna - Law360
Here's How Much You Would Have Made Owning Cigna Group Stock In The Last 20 Years - Benzinga
Cigna Group (CI) Reaffirms 2025 Financial Outlook - GuruFocus
Cigna Reaffirms 2025 Earnings Projection Amid Investor Meetings - TipRanks
Virtual-Care Company Omada Files IPO Papers - Healthcare Innovation
Forfeiture Lawsuit Filed Against Cigna; Intuit Reaches Settlement - planadviser
Cigna employees file a 401(k) lawsuit, alleging misuse of forfeited funds - BenefitsPRO
Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing DistortionCVS Health (NYSE:CVS), Cigna Group (NYSE:CI) - Benzinga
The Cigna Group Stock Outlook: Is Wall Street Bullish or Bearish? - MSN
Cigna Hit With Forfeiture Lawsuit; Intuit Reaches Settlement - plansponsor
Trump’s Drug Pricing Order Targets PBMs—Pharma Stocks May Escape the Worst - Investing.com
CI Q1 Earnings Call: Cigna Delivers Revenue Beat and Focuses on Healthcare Innovation - Yahoo Finance
Exclusive | UnitedHealth Group Is Under Criminal Investigation for Possible Medicare Fraud - WSJ
Cigna (CI) Loses Oncology Leader to The Oncology Institute | CI Stock News - GuruFocus
Aetna, Cigna Can't Nix Suit Over Late Emergency Benefit Bills - Law360
Why We Don’t Use Statements: Cigna Criticized After Denying Life-Saving Lung Transplant Before Media Backlash - NBC Palm Springs
Jeff Auxier's Strategic Moves: A Closer Look at The Cigna Group and More - Yahoo Finance
Cigna Group Stock (CI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):